Impact of Covid-19 Pandemic on Management of Head and Neck Cancers
Head and Neck CancerCovid191 moreSince its emergence in late December 2019, the SARS-CoV-2 coronavirus has spread rapidly, causing a global health crisis. The disease caused by this highly contagious respiratory virus is called COVID-19. At the beginning of August 2020, there were more than 194,000 confirmed cases in France - including approximately 16,000 cases in the Hauts-de-France area - and more than 30,300 deaths. Cancer patients are generally susceptible to respiratory infections, and CoV-2-SARS is no exception. Early Chinese studies reported a higher rate of CoV-2-SARS infection in people with cancer (or a history of cancer) than in the general population, with more severe forms and with an increased risk if surgery or chemotherapy is performed in the month prior to infection. The purpose of this study is to describe the management modalities of patients with H&N (Head and Neck) cancer during the COVID-19 pandemic in the Maxillofacial Surgery Department of CHU Amiens-Picardie.
Organ Preservation in the Multispeciality Therapy of Stage II-IV Locally Advanced Head and Neck...
Head and Neck CancerThis protocol was opened to collect long term survival information on subjects enrolled in a previous study which evaluated the impact of neoadjuvant chemotherapy and concomitant chemoradiotherapy with organ preserving optional surgery on overall survival, time to progression, pattern of disease recurrence in patient with locally advanced head and neck cancer. The last surviving subject was last treated in 1989, and was lost to follow up in 2010.
The Role of FDG PET in Radiation Treatment Planning for Head and Neck Cancers
Head and Neck CancerIn patients with cancer of the head and neck and rectum, knowing the exact location of the tumor is important for designing the radiation field to ensure delivery of high dose of radiation to the tumor while sparing surrounding normal tissues. A new medical imaging method which is a combination of positron emission tomography (PET) and computed tomography (CT) scan, has shown promise in helping the radiation oncologist in defining the exact location and extent of the tumor in certain cancers such as lung cancers. Therefore the purpose of this study is to determine if these imaging methods can be used in combination with the standard radiation treatment planning procedure to improve the accuracy to targeting your tumor with radiation. In addition the PET-CT scan, similar to the PET scan alone with better resolution, can be used to determine whether the tumor has spread to any part of the body outside of the head and neck sites.
Review of Palliative Radiotherapy in the Management of Advanced Head and Neck Cancer
Head and Neck CancerTo describe the charactersitics of patients with advanced head and neck cancer treated with palliative intent and determine outcome in terms of symptom control and toxicity
The Physiological Response to Routine Head and Neck Cancer Surgery
Head and Neck CancerThe main objective of this pilot study is to observe and document the range of changes in the blood concentrations of certain hormones, inflammatory chemicals and immune chemicals in response to the stimulus of Head and Neck cancer
Biopsy of Human Tumors for Cancer Stem Cell Characterization: a Feasibility Study
Head and Neck CancerHead and Neck CancersTo see if a limited sampling of tumor tissue from human subjects is a feasible way to gather adequate tissue for cancer stem cell quantification.
Evaluating Taste and Smell Function and Food and Taste Preferences of Head and Neck Cancer Patients...
Head and Neck CancerChanges to taste and smell have been reported in head and neck cancer patients who undergo radiation and chemotherapy. This may cause food to be unappealing and can lead to a reduced food intake. Thsi study will increase our understanding of taste and smell changes and how it relates to food and taste preferences.
A Reminder App to Reduce Radiation Dermatitis Rates in Patients With Head-and-Neck Cancer
Radiation DermatitisRadiation-induced Oral MucositisThe goal of this randomized trial is to investigate whether the addition of a reminder app to standard care leads to a reduction of dermatitis and oral mucositis during radio(chemo)therapy for locally advanced squamous cell carcinoma of the head-and-neck (SCCHN). The primary endpoint is the rate of patients experiencing grade ≥2 radiation dermatitis at 60 Gy of radiotherapy. 80 patients are required per arm within the full analysis set. Taking into account that 5% of patients will not qualify for full analysis set, 168 patients should be randomized. If the addition of a reminder app to standard care will result in a significant reduction of radiation toxicity, it could become a helpful tool for these patients.
A Predictive Nomogram for Trismus After Radiotherapy for Head and Neck Cancer
TrismusBackground: The aim of this study is to develop a prediction model for radiation-induced trismus (maximal interincisal distance equal to or less than 35 mm) based on a multivariable analysis of dosimetric and clinical factors.
Hearing Loss and the Effects of Statin Drugs in People With Head and Neck Squamous Cell Carcinoma...
Head and Neck NeoplasmsHearing Disorder1 moreBackground: Cisplatin is a chemotherapy drug. It is used to treat head and neck squamous cell carcinoma (HNSCC) and other cancers. It can cause hearing loss for some people. It is not known how many people will get hearing loss from cisplatin. It is also not known what other factors might influence who gets hearing loss. Factors could include age, sex, noise exposure, and other drugs the person is taking. Statins are drugs used to lower cholesterol. Statins may also reduce cisplatin-induced hearing loss. Objectives: To see if statins reduce hearing loss in people getting cisplatin therapy to treat HNSCC. To find out how many people taking cisplatin get hearing loss from it. To find out if other factors might influence whether cisplatin causes hearing loss. Eligibility: People ages 18 and older who are getting treatment with cisplatin for HNSCC Design: Participants will be screened with a review of their medical records. Participants will have 3 visits. These will be before the onset of cisplatin therapy, at about 4 weeks after they finish therapy, and about 6 months after they finish therapy. Each visit will include: Medication history Audiogram/hearing tests. Participants will wear headphones and indicate when they hear different sounds. Questions about their noise exposure history and whether they have ringing in the ears